8-K: NEXGEL Doubles Q2 Revenue, Narrows Losses

NEXGEL, Inc. reported a 100.3% increase in second quarter 2025 revenue to $2.88 million, significantly improving gross profit margins and reducing net and EBITDA losses.

Summary

• Net Revenue for Q2 2025 reached $2.88 million, a 100.3% increase compared to $1.44 million in Q2 2024.
• Gross Profit for the quarter was $1.26 million, up from $0.29 million in Q2 2024.
• Gross Profit Margin improved to 43.6% in Q2 2025, compared to 20.3% in Q2 2024.
• Net loss attributable to NEXGEL stockholders decreased to $0.67 million in Q2 2025, from $0.89 million in Q2 2024.
• Adjusted EBITDA loss narrowed to $0.42 million in Q2 2025, compared to $0.79 million in Q2 2024.
• The company reiterated its 2025 revenue guidance of $13 million and its goal to achieve positive EBITDA during the year.
• As of June 30, 2025, cash balance was approximately $0.73 million.
• Subsequent to the quarter, NEXGEL expanded its partnership with STADA, receiving a $1 million advance in non-dilutive capital.
• Also subsequent to the quarter, the company closed on financings for $1.05 million in gross proceeds.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to exceptional revenue growth, significant margin expansion, and a substantial reduction in losses, coupled with successful capital raises and reiterated optimistic full-year guidance. The company is demonstrating strong operational momentum towards profitability.

Positives

• Achieved 100.3% year-over-year revenue growth in Q2 2025, reaching $2.88 million.
• Significantly improved Gross Profit Margin to 43.6% in Q2 2025 from 20.3% in Q2 2024.
• Reduced Net Loss attributable to stockholders to $0.67 million in Q2 2025 from $0.89 million in Q2 2024.
• Adjusted EBITDA loss narrowed to $0.42 million in Q2 2025, showing a steady decline in losses.
• Secured $1 million in non-dilutive capital from an expanded partnership with STADA.
• Successfully closed on financings for $1.05 million in gross proceeds, supporting growth initiatives.
• Growth driven by increased consumer demand for branded products and new contract manufacturing agreements.

Negatives

• Continued to report a net loss of $0.67 million for Q2 2025.
• EBITDA and Adjusted EBITDA remained negative, at ($0.53) million and ($0.42) million respectively, for Q2 2025.
• Cash balance as of June 30, 2025, was $0.73 million, a decrease from $1.807 million at December 31, 2024.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from anticipated results.
• Achievement of future growth opportunities in the second half of 2025, including new consumer product launches and onboarding new contract manufacturing customers, is subject to various factors.
• The ability to achieve the reiterated 2025 revenue guidance of $13 million and positive EBITDA during the year is subject to market conditions and operational execution.

Future Outlook

The company expects significant growth opportunities in the second half of 2025, driven by new consumer product launches for its brands and the onboarding of new contract manufacturing customers. It remains confident in its previously issued guidance for 2025, targeting $13 million in revenue and achieving positive EBITDA during the year.

Management Comments

• "For the second quarter of 2025 we reported strong revenue and gross margin with a steady decline of our Adjusted EBITDA loss as we head into seasonally a strong second half of the year."
• "The year-over-year growth was led by growth in consumer demand for our branded products and new agreements in contract manufacturing."
• "In both parts of our business, we expect significant growth opportunities in the second half of 2025 as new consumer product launches for our brands come online and we onboard new contract manufacturing customers in our robust pipeline."
• "Subsequent to the quarter, we expanded our partnership with STADA, which includes a $1 million advance in non-dilutive capital to support product launches and marketing efforts."
• "Additionally we closed on financings for $1.05 million in gross proceeds, which is sufficient to support our upcoming growth initiatives."
• "We remain confident in our previously issued guidance for 2025 of $13 million in revenue and to achieve positive EBITDA during the year."

Industry Context

NEXGEL operates in the healthcare, beauty, and over-the-counter (OTC) product sectors, specializing in ultra-gentle, high-water-content hydrogel products. The reported growth in both branded consumer products and contract manufacturing indicates a positive trend within its niche, leveraging consumer demand and strategic partnerships like the expanded agreement with STADA, a global pharmaceutical company.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks. Therefore, a direct comparison to industry standards with specific entities is not possible based solely on the provided information.

Related Party Transactions

• Accounts payable related party of $0.447 million as of June 30, 2025, down from $0.531 million as of December 31, 2024.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability metrics, and successful capital raises, which could lead to increased share value.
• Customers: Potential for new product offerings and continued supply from expanded manufacturing capabilities.
• Employees: Growth in operations and new initiatives may lead to job stability or expansion.
• Creditors: Improved financial health and capital raises may enhance the company's ability to meet its obligations.

Next Steps

• New consumer product launches for branded products in the second half of 2025.
• Onboarding new contract manufacturing customers in the second half of 2025.
• Continued efforts to achieve $13 million in revenue for 2025.
• Continued efforts to achieve positive EBITDA during 2025.

Key Dates

Recommendation

The company demonstrated exceptional Q2 2025 performance with 100.3% revenue growth and a significant increase in gross profit margin to 43.6%. Losses (Net Loss, EBITDA, Adjusted EBITDA) narrowed substantially, indicating a strong trajectory towards profitability. The reiteration of $13 million revenue guidance and positive EBITDA for 2025, combined with recent non-dilutive capital from STADA and additional financings, provides a clear path for continued growth and financial improvement. This strong operational momentum and clear future outlook make it a compelling investment.

Keywords

NEXGEL, Hydrogel, Healthcare products, Beauty products, OTC products, Contract manufacturing, Financial results, Earnings, NASDAQ: NXGL, STADA, Silly George